Jul 24, 2025, 07:51

Investigator-Initiated Multinational Early-Stage Innovative Clinical Trials for Paediatric Cancer

This Research & Innovation Action under Horizon Europe will fund multinational, academic-led Phase I/II trials of novel, targeted treatments and companion diagnostics tailored for children (0-14 years) and adolescents (15-19 years) with cancers that have poor prognosis. Projects must demonstrate safety, preliminary efficacy, reduced acute/long-term toxicity, and generate open-science datasets for the future UNCAN.eu platform.

Eligibility Criteria:

Consortia of at least three independent legal entities from Horizon Europe Member States or Associated Countries
Academic sponsors with paediatric oncology trial experience and access to patient populations
Inclusion of multidisciplinary partners (clinicians, data scientists, SSH experts, patient advocates, SMEs, regulators)
Trial protocols addressing socio-economic, biological, sex/gender stratification and companion diagnostic development
Commitment to metadata registration in the European Health Data Space and open-science tool sharing via UNCAN.eu

Funding Details:

Action Type: HORIZON-RIA (Research & Innovation Action)
Total Budget: €25 000 000
Indicative Grants: 4 grants of €6 000 000–€8 000 000 each
Grant Model: Single-stage, lump-sum Horizon-AG-LS

Deadline:

Submit via the EU Funding & Tenders Portal by 16 September 2025, 17:00 Brussels time.

Where to Apply & More Info:

EU Funding & Tenders Portal – search HORIZON-MISS-2025-02-CANCER-04
Horizon Europe Work Programme 2025, “Supporting the implementation of the Cancer Mission”
Horizon Europe Programme Guide and Online Manual on the Portal

Cancer Mission companion diagnostics Horizon Europe Multidisciplinary multinational clinical trials open science paediatric oncology Phase I/II UNCAN.eu

Marking One Year of Progress in IDH-Mutant Glioma Treatment - Servier Pharmaceuticals

James Whale Dies at 74: The Radio Icon’s Long Fight Against Kidney Cancer

A Pivotal Day for Geron

Top GU Immunotherapy Trials to Watch at ESMO 2025

Julie Gralow Received the 2025 NCG Lifetime Achievement Award in Oncology